Rheumatology Network's Top 5: July 23, 2021

July 23, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 23, 2021.

First-Line Biologics Reduce Glucocorticoid Exposure in Patients With Systemic Juvenile Idiopathic Arthritis

Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.

Click the image to view the story.

Rheumatoid Arthritis Quiz: Treat-to-Target

Treat-to-target remains a key strategy for the treatment of rheumatoid arthritis. However, some changes to the recommendations were made in the 2021 American College of Rheumatology Guidelines on the Management of Rheumatoid Arthritis. Check your knowledge on how to approach a treat-to-target strategy with this quiz.

Click the image to view the story.

PainTRAINER Program Improves Outcomes for Patients With Systemic Lupus Erythematosus

The painTRAINER program included 8 weekly modules, in addition to coping skill activities, in which investigators measured outcomes including the Pain Catastrophizing Scale, pain interference, physical function, anxiety and depression, fatigue, and sleep disturbances.

Click the image to view the story.

Rheumatology Network's Spotlight: Clinical Updates in Psoriatic Arthritis July 2021

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

Click the image to view the story.

Gradual Glucocorticoid Withdrawal Does Not Increase Flares in Systemic Lupus Erythematosus

Glucocorticoid withdrawal over a prolonged period of time did not increase clinical flares or damage for patients with inactive systemic lupus erythematosus.

Click the image to view the story.